Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Should Quantitative Measures and Management of Rheumatoid Arthritis Include More Than Control of Inflammatory Activity?

Theodore Pincus, Martin J. Bergman and Yusuf Yazici
The Journal of Rheumatology October 2021, jrheum.210953; DOI: https://doi.org/10.3899/jrheum.210953
Theodore Pincus
Rush University Medical Center, Chicago, Illinois; Drexel University, College of Medicine, Philadelphia, Pennsylvania; NYU School of Medicine, New York, New York, USA. TP is president of Medical History Services LLC, which receives royalties and license fees from for-profit pharmaceutical companies and electronic medical record companies for use of MDHAQ and RAPID3. All license fees are used to support further development of quantitative measurement in clinical rheumatology care using patient and physician questionnaires. MJB receives speaking/consulting fees from AbbVie, Amgen, BMS, GSK, Janssen, Merck, Novartis, Pfizer, Sandoz, Sanofi, and Scifer; and is a shareholder of Merck and Johnson & Johnson. YY receives research support from Amgen and BMS, and is a consultant for Amgen, BMS, and Sanofi. Address correspondence to Dr. T. Pincus, Rush University, 1611 West Harrison Street, Suite 510, Chicago, IL 60612, USA. Email: tedpincus@gmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin J. Bergman
Rush University Medical Center, Chicago, Illinois; Drexel University, College of Medicine, Philadelphia, Pennsylvania; NYU School of Medicine, New York, New York, USA. TP is president of Medical History Services LLC, which receives royalties and license fees from for-profit pharmaceutical companies and electronic medical record companies for use of MDHAQ and RAPID3. All license fees are used to support further development of quantitative measurement in clinical rheumatology care using patient and physician questionnaires. MJB receives speaking/consulting fees from AbbVie, Amgen, BMS, GSK, Janssen, Merck, Novartis, Pfizer, Sandoz, Sanofi, and Scifer; and is a shareholder of Merck and Johnson & Johnson. YY receives research support from Amgen and BMS, and is a consultant for Amgen, BMS, and Sanofi. Address correspondence to Dr. T. Pincus, Rush University, 1611 West Harrison Street, Suite 510, Chicago, IL 60612, USA. Email: tedpincus@gmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yusuf Yazici
Rush University Medical Center, Chicago, Illinois; Drexel University, College of Medicine, Philadelphia, Pennsylvania; NYU School of Medicine, New York, New York, USA. TP is president of Medical History Services LLC, which receives royalties and license fees from for-profit pharmaceutical companies and electronic medical record companies for use of MDHAQ and RAPID3. All license fees are used to support further development of quantitative measurement in clinical rheumatology care using patient and physician questionnaires. MJB receives speaking/consulting fees from AbbVie, Amgen, BMS, GSK, Janssen, Merck, Novartis, Pfizer, Sandoz, Sanofi, and Scifer; and is a shareholder of Merck and Johnson & Johnson. YY receives research support from Amgen and BMS, and is a consultant for Amgen, BMS, and Sanofi. Address correspondence to Dr. T. Pincus, Rush University, 1611 West Harrison Street, Suite 510, Chicago, IL 60612, USA. Email: tedpincus@gmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

We agree strongly with Kremer et al that "metrics are essential for evaluating disease activity in patients with rheumatoid arthritis (RA)."1 Nonetheless, data reported from the Corrona and the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) registries for Clinical Disease Activity Index (CDAI) and Routine Assessment of Patient Index Data 3 (RAPID3) are quite similar to those reported in the initial 2008 RAPID3 report.2

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 50, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Should Quantitative Measures and Management of Rheumatoid Arthritis Include More Than Control of Inflammatory Activity?
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Should Quantitative Measures and Management of Rheumatoid Arthritis Include More Than Control of Inflammatory Activity?
Theodore Pincus, Martin J. Bergman, Yusuf Yazici
The Journal of Rheumatology Oct 2021, jrheum.210953; DOI: 10.3899/jrheum.210953

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Should Quantitative Measures and Management of Rheumatoid Arthritis Include More Than Control of Inflammatory Activity?
Theodore Pincus, Martin J. Bergman, Yusuf Yazici
The Journal of Rheumatology Oct 2021, jrheum.210953; DOI: 10.3899/jrheum.210953
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Interstitial Lung Disease?
  • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
  • Desk Rejections: Not Without Due Deliberation
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire